Cargando…

Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report

The outcomes of COVID-19 in kidney transplant recipients have shown high mortality. In addition to their immunocompromised states, kidney transplant recipients frequently have certain exacerbation risk comorbidities of COVID-19, such as diabetes mellitus, hypertension, and chronic kidney disease. Se...

Descripción completa

Detalles Bibliográficos
Autores principales: Uematsu, Hikaru, Shinoda, Kazunobu, Saito, Akinobu, Sakai, Ken
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379217/
https://www.ncbi.nlm.nih.gov/pubmed/35972687
http://dx.doi.org/10.1007/s13730-022-00724-z
_version_ 1784768629869379584
author Uematsu, Hikaru
Shinoda, Kazunobu
Saito, Akinobu
Sakai, Ken
author_facet Uematsu, Hikaru
Shinoda, Kazunobu
Saito, Akinobu
Sakai, Ken
author_sort Uematsu, Hikaru
collection PubMed
description The outcomes of COVID-19 in kidney transplant recipients have shown high mortality. In addition to their immunocompromised states, kidney transplant recipients frequently have certain exacerbation risk comorbidities of COVID-19, such as diabetes mellitus, hypertension, and chronic kidney disease. Several concomitant diseases develop during the course of COVID-19, one of which is thromboembolism, which can potentially lead to a critical condition. However, thromboembolic complications in kidney transplant recipients with COVID-19 have not been fully addressed in previous studies. A 62-year-old man, who underwent kidney transplantation 17 years ago, was diagnosed with COVID-19 and was admitted to our hospital. Although the patient was in remission at the start of the hospitalization, his condition became severe on day 7 after admission, with fever, elevated white blood cell counts (10,000/μL) and a high C-reactive protein level (6.9 mg/dL). Although the patient was not under forced bed rest, an ultrasound study on day 10 detected deep venous thrombosis (DVT), with an elevated D-dimer level (6.2 µg/dL). We withdrew the mycophenolate mofetyl and the tacrolimus dosage but did not administer any specific treatment for COVID-19. The patient achieved successful clearance of SARS-CoV-2 on day 16. The DVT disappeared after systematic heparin treatment and oral rivaroxaban for 2 months. DVT occurred in a kidney transplant recipient with COVID-19 who was not bedridden and might manifest when the clinical status was exacerbated during hospitalization.
format Online
Article
Text
id pubmed-9379217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Nature Singapore
record_format MEDLINE/PubMed
spelling pubmed-93792172022-08-16 Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report Uematsu, Hikaru Shinoda, Kazunobu Saito, Akinobu Sakai, Ken CEN Case Rep Case Report The outcomes of COVID-19 in kidney transplant recipients have shown high mortality. In addition to their immunocompromised states, kidney transplant recipients frequently have certain exacerbation risk comorbidities of COVID-19, such as diabetes mellitus, hypertension, and chronic kidney disease. Several concomitant diseases develop during the course of COVID-19, one of which is thromboembolism, which can potentially lead to a critical condition. However, thromboembolic complications in kidney transplant recipients with COVID-19 have not been fully addressed in previous studies. A 62-year-old man, who underwent kidney transplantation 17 years ago, was diagnosed with COVID-19 and was admitted to our hospital. Although the patient was in remission at the start of the hospitalization, his condition became severe on day 7 after admission, with fever, elevated white blood cell counts (10,000/μL) and a high C-reactive protein level (6.9 mg/dL). Although the patient was not under forced bed rest, an ultrasound study on day 10 detected deep venous thrombosis (DVT), with an elevated D-dimer level (6.2 µg/dL). We withdrew the mycophenolate mofetyl and the tacrolimus dosage but did not administer any specific treatment for COVID-19. The patient achieved successful clearance of SARS-CoV-2 on day 16. The DVT disappeared after systematic heparin treatment and oral rivaroxaban for 2 months. DVT occurred in a kidney transplant recipient with COVID-19 who was not bedridden and might manifest when the clinical status was exacerbated during hospitalization. Springer Nature Singapore 2022-08-16 /pmc/articles/PMC9379217/ /pubmed/35972687 http://dx.doi.org/10.1007/s13730-022-00724-z Text en © The Author(s) under exclusive licence to The Japan Society of Nephrology 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
spellingShingle Case Report
Uematsu, Hikaru
Shinoda, Kazunobu
Saito, Akinobu
Sakai, Ken
Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report
title Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report
title_full Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report
title_fullStr Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report
title_full_unstemmed Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report
title_short Deep venous thrombosis in a kidney transplant recipient with COVID-19: a case report
title_sort deep venous thrombosis in a kidney transplant recipient with covid-19: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9379217/
https://www.ncbi.nlm.nih.gov/pubmed/35972687
http://dx.doi.org/10.1007/s13730-022-00724-z
work_keys_str_mv AT uematsuhikaru deepvenousthrombosisinakidneytransplantrecipientwithcovid19acasereport
AT shinodakazunobu deepvenousthrombosisinakidneytransplantrecipientwithcovid19acasereport
AT saitoakinobu deepvenousthrombosisinakidneytransplantrecipientwithcovid19acasereport
AT sakaiken deepvenousthrombosisinakidneytransplantrecipientwithcovid19acasereport